It is rare for a person with a blood clotting disorder to have a low platelet count. Usually, when you have a low platelet count, you’ll have difficulty forming blood clots.
The fact that the J&J vaccine is associated with more cases of TTS than what the experts initially believed solidified their decision to prefer Pfizer and Moderna.
Note that besides J&J, AstraZeneca has also been linked to TTS. The United States currently does not approve the use of AstraZeneca.
Why US Authorities Continue To Support the J&J Vaccine
After learning more about TTS, the rare blood clot disorder associated with the J&J vaccine, you may be wondering, “Why do health authorities continue to support it?” There are several reasons.
First, experts believe that receiving any vaccine is far better than being unvaccinated. COVID-19, after all, doesn’t just cause hospitalization and intubation; it might also lead to long-term side effects.
Secondly, TTS “continues to be a rare event.”
And finally, in the United States, J&J is the only available vaccine for people who can’t — or won’t — get an mRNA vaccine. Some people might also prefer J&J because they don’t like getting two doses.
They also mentioned that withdrawing support for the previously approved vaccine means people have fewer choices, and that may have an effect on the people’s confidence in the COVID-19 vaccination program.
The US Center for Disease Control made a statement saying they prefer mRNA vaccines, Moderna and Pfizer, over the viral vector J&J vaccine. The recommendation was made after the officials learned that the cases of thrombosis with thrombocytopenia syndrome (TTS) after J&J vaccination were higher than they initially thought. They also considered the vaccine effectiveness. Despite this, they continue to support the single-shot vaccine after weighing the benefits and risks.
More Health News here.